Natural Killer Cell Therapy Market Is Going to Boom| Novartis, Gilead Sciences, Bristol Myers Squibb
PUBLISHED Monday, April 27, 2026 · coherent market insights
AI BRIEFING
- ⬤ Novartis and Gilead Sciences lead in NK cell therapy development
- ⬤ Bristol Myers Squibb's nintedanib gets FDA approval for NK cell therapy
- ⬤ Increasing adoption of immunotherapy drives growth in NK cell therapy market
ADVERTISEMENT